Back to search results

18F-mFBG Imaging for Heart Failure with Ischemic Cardiomyopathy

This study is looking at a new way to image the heart using a special PET scan. Researchers are testing a drug called 18F-metaFluorobenzylguanidine to see how well it shows nerve activity in the heart muscle (myocardial sympathetic innervation) in people with stable heart failure caused by blocked arteries (ischemic cardiomyopathy). You would be eligible if you have stable heart failure from ischemic cardiomyopathy, a heart pumping ability (LVEF) of 35% or less, and an implanted defibrillator (ICD) for at least 12 months. The study aims to see how much the 18F-metaFluorobenzylguanidine is taken up by the heart and how this relates to blood flow in the heart. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 20 participants. It will evaluate the imaging agent 18F-metaFluorobenzylguanidine.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be followed for 24 hours after receiving the study drug for PET imaging.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06965621

18F-mFBG Imaging for Myocardial Sympathetic Innervation

Recruiting
PHASE2Ages 18+InterventionalDiagnostic
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
~20 participants
Updated 2026-07-01 on ClinicalTrials.gov
What's tested:18F-metaFluorobenzylguanidineRubidium-82

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Quantify the degree of reduced myocardial 18F-mFBG uptake in adult HF subjects with well-characterized coronary heart disease
Measured over 24 hours from administration of the study drug for PET imaging and safety follow-up

Conditions

Heart Failure
Ischemic Cardiomyopathy
ICD Patients

Explore related trials

Generalized ischemic myocardial dysfunctionHeart Failure

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • K. Lance Gould, MD · PRINCIPAL_INVESTIGATOR · Professor of Medicine, McGovern Medical School, UTHealth

Who to contact

K. Lance Gould, MD
[email protected]
713-704-2489
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Stable heart failure from ischemic cardiomyopathy, LVEF \< or = 35%, ICD implantation for at least 12 months

Exclusion

Unstable coronary artery disease, no ICD implantation

What this trial measures

  • Quantify the degree of reduced myocardial 18F-mFBG uptake in adult HF subjects with well-characterized coronary heart disease24 hours from administration of the study drug for PET imaging and safety follow-up

    Obtain computer quantification of global and/or regional differences in myocardial sympathetic innervation (based on 18F-mFBG uptake) between subjects who have and have not experienced an appropriate ICD activation within the previous 12 months